Tiziana Life Sciences Share Discussion Threads

[jpuff] 27/7/2018 17:42

I never jumped out in the first place Stenick - hence my gripe when I bought in big time for me at 200p+ ouch! Hoping to recover my loses now and daring myself to average down perhaps. Still if all goes well I'm sure we'll see 200p+ again in the Nasdaq listing goes well and the products of course.

[stenick] 27/7/2018 17:27

Btw did you jump back in again jpuff? Don’t answer if you don’t want to. Asmodeus where have you been, relax don’t do it.

[jpuff] 27/7/2018 17:01

Don't get yourself in a Tizzi(ana) now Stenick!

[stenick] 27/7/2018 16:59

Reasons to be cheerful 1 2 3. Lol

[asmodeus] 27/7/2018 16:55

who's wielding the rhythm stick?

[stenick] 27/7/2018 16:24

Broke through, ‘The only way is up baby’ another hit.

[stenick] 27/7/2018 14:55

24 hrs from TLSA, and that was a hit as well.

[stenick] 27/7/2018 12:07

If your looking for guarantees PUG you won’t get them in this game.

[stenick] 27/7/2018 12:05

They all have to state that it’s a risk, no matter if it is or it isn’t. And high net worth people do not want to loose money so they reasearch or there advisers do and woobetide them if they advise them wrongly.

[pugugly] 27/7/2018 11:59

Stenick_ Your quote above means that the shares are considered very very high risk and only for punters you would not be hurt (materially) if a major crash - A bit like being a Zuckerberg - loose $19bn but probably not a material loss to him as only a paper loss !!!!

[stenick] 27/7/2018 09:20

I like the bit about the ADS’s only being offered to high net worth individuals and companies through licensed proffesional investment advisors.
Come on you lot out there ‘time to pile back in’ the higher this goes the higher we start on the Nasdaq. As always check what I’ve said and DYOR. Good luck all.

[jpuff] 27/7/2018 08:55

I agree with that Stenick. With almost zero trades recently on AIM they need to migrate to a market where at least there is some liquidity and where they might get noticed!

[stenick] 27/7/2018 08:52

I think this is a good thing, will now be traded on Nasdaq.
If it climbs on nasdaq, aim has to follow and vice versa. IMO

[jpuff] 27/7/2018 08:12

Not sure this will make much difference but at least a sign of life!Tiziana Life Sciences PLC US Registration Statement for Proposed OfferingSource: UK Regulatory (RNS & others)TIDMTILSRNS Number : 9251VTiziana Life Sciences PLC27 July 2018THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014Tiziana Life Sciences plc ("Tiziana" or the "Company")Tiziana Files US Registration Statement for Proposed OfferingLondon, 27 July 2018 - Tiziana Life Sciences plc (AIM: TILS) (the "Company" or "Tiziana"), a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, announces the filing of a registration statement on Form F-1 with the U.S. Securities Exchange Commission ("SEC") relating to a proposed initial public offering of its American Depositary Shares ("ADSs"), representing ordinary shares of nominal value GBP0.03 each in the capital of the Company ("Ordinary Shares"), in the United States (the "Offering").All ADSs to be sold in the Offering will be offered by the Company. The number of Ordinary Shares to be represented by each ADS, the number of ADSs to be offered and the price range for the Offering have not yet been determined. The number of Ordinary Shares represented by ADSs comprised in the Offering will be within existing shareholder authorities.The Company has applied to have its ADSs listed on the Nasdaq Capital Market under the symbol "TLSA". Upon completion of the Offering, the Ordinary Shares will continue to be admitted to trading on AIM, a market of the London Stock Exchange plc, under the symbol "TILS".Laidlaw & Company (UK) Ltd. is acting as the representative of the underwriters in respect of the Offering.The Offering will be made only by means of a prospectus, which, for the avoidance of doubt, will not constitute a "prospectus" for the purposes of the Prospectus Directive (as defined below) and has not been reviewed by any competent authority in any Member State (as defined below).When available, copies of the preliminary prospectus relating to and describing the terms of the Offering may be obtained from Laidlaw & Company Ltd., Attention: Syndicate Department, 521 Fifth Avenue, New York, NY 10175, by telephone at +01 (0)212 953 4917 or by email at [e-mail]. Electronic copies of the final prospectus supplement and accompanying prospectus will also be available on the website of the SEC at www.sec.gov. A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy these securities be accepted, prior to the time the registration statement becomes effective. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.The person who arranged for the release of this announcement on behalf of the Company was Gabriele Cerrone, Chairman and founder of Tiziana.For readers in the European Economic AreaIn any member state in the European Economic Area (each, a "Member State") that has implemented the Prospectus Directive (as defined below), this announcement is only addressed to and directed at qualified investors in that EEA Member State within the meaning of the Prospectus Directive. The term "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, to the extent implemented in each relevant Member State), together with any relevant implementing measure in the relevant Member State.For readers in the United KingdomThis announcement, in so far as it constitutes an invitation or inducement to enter into investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000, as amended) in connection with the securities which are the subject of the Offering described in this announcement or otherwise, is being directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments who fall within Article 19(5) ("Investment professionals") of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (iii) certain high value persons and entities who fall within Article 49(2)(a) to (d) ("High net worth companies, unincorporated associations etc.") of the Order; or (iv) any other person to whom it may lawfully be communicated (all such persons in (i) to (iv) together being referred to as "relevant persons"). The ADSs offered in the Offering are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such ADSs will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents.For distributorsSolely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the ADSs have been subject to a product approval process, which has determined that such securities are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment").Notwithstanding the Target Market Assessment, "distributors" (for the purposes of the MiFID II Product Governance Requirements) should note that: the price of ADSs may decline and investors could lose all or part of their investment; the ADSs offer no guaranteed income and no capital protection; and an investment in ADSs is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Offering.For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to ADSs.Each distributor is responsible for undertaking its own target market assessment in respect of the ADSs and determining appropriate distribution channels.Forward-Looking StatementsCertain statements made in this announcement are forward-looking statements including with respect to the creation of a trading market for ADSs representing the Ordinary Shares in the United States. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.For further enquiries: Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder [phone] Laidlaw & Company (UK) Ltd. Matt Dormer / James Ahern [phone] Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Jo Turner [phone] Stockdale Securities Limited (Broker) Andy Crossley / Antonio Bossi [phone] This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.ENDMSCFMGZNDVGGRZM(END) Dow Jones NewswiresJuly 27, 2018 02:00 ET (06:00 GMT)

[stenick] 25/7/2018 20:28

Jpuff study results are not confirmed yet on clinictrials.gov. So maybe that’s the hold up.

[stenick] 25/7/2018 20:25

Studies final statement ‘. As presented in this study, JQ1 and Milciclib suppress MYC in different ways, causing a synergistic inhibition rather than an additive repression. We therefore propose using these inhibitors in combination for treating MYC-dependent, aggressive pediatric brain tumors.’

What that means I don’t really know but at a guess I think it works with brain tumours in paediatrics.

[stenick] 25/7/2018 18:40

I think he would be better selling to a big pharma if he can, then everyone’s a winner. Trying to go it alone is tough, after all he only owns the licence to achieve not fail as that reverts back to nervioms the Italian owners. I did actually come across a few years ago that Vatican has an interest, but don’t quote me on this.
So if it’s a scam it’s a scam but who knows.

[jpuff] 25/7/2018 18:06

Maybe the CEO who holds a very large % wants to take it private? Hope not as that would be curtains for us. No buyers interested even at these extreme depressed levels which makes me think the worst. I'd like to be proven wrong and need some miracle now just to recover my original investment!

[stenick] 25/7/2018 17:51

Perhaps they don’t know why the share price collapsed, and in previous statements over the years they said they would not give updates so I don’t expect an update except on news that materially effects the company.

[stenick] 25/7/2018 17:30

Yes I know, but they have got money, the trials are on going, with very good results. And as you say traders are not interested in jargon they just want profits, Okyo pharma seems to be the flavour at the mo.
Btw I got confused as I do a lot of web trawling, but JQ1 was not sold for 12billion but it was an LA startup that drained your blood and genetically modified it and put it back, sorry no mis info intended

[jpuff] 25/7/2018 17:11

And still no mention from the directors of the company as to why the share price has collapsed from 240p to 36p. I'll leave you to work out the percentage, but it's looking pretty terminal to me!

[stenick] 25/7/2018 16:57

Still plenty of sellers, probably all diving into another one. Stockdale must have loads of shares now, probably an office full!

[jpuff] 20/7/2018 15:26

Thanks for the details Stenick. My tumour although obviously unwelcome and a complete shock at the time was a Meningioma of lower grade otherwise I would be here typing now - cf some of the nastier ones. I did buy in low originally and added more near the peak particularly on the back of the bullish Beauforts buy notes. So I'm now wondering whether to average down or not, but given how so very quiet it's gone here I can't see much point until news comes out. However if a bid does come along it could gap up very sharply and hey presto the buy low opportunity is lost.